Utah is currently home to 1240 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis
NCT04566666
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Site # 18, Springville, Utah
Conditions: Moderate to Severe Plaque Psoriasis
Register for Updates
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
NCT04475926
Recruiting
This study will follow participants who are screened and confirmed with a genetic diagnosis of Limb-girdle muscular dystrophy type 2E (LGMD2E/R4), Limb-girdle muscular dystrophy type 2D (LGMD2D/R3), Limb-girdle muscular dystrophy type 2C (LGMD2C/R5), or Limb-girdle muscular dystrophy type 2A (LGMD2A/R1). These enrolled participants will be followed to evaluate mobility and pulmonary function for up to 3 years after enrollment. Additional participant data will be collected from the time the indiv... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
03/26/2024
Locations: University of Utah Hospital, Salt Lake City, Utah
Conditions: Limb-girdle Muscular Dystrophy
Register for Updates
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
NCT05143840
Recruiting
This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). The aim of this study is to evaluate the efficacy and safety of asciminib in newly diagnosed CML-CP. Patients will receive asciminib 80 mg orally once daily during the single asciminib phase. Response is determined by PCR (polymerase chain reaction) blood test during the study. Patients who have not... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
Register for Updates
SPIROMICS Study of Early COPD Progression (SOURCE)
NCT05033990
Recruiting
This is an observational study of 1000 participants to further define the nature of early chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals. The study has three main goals: To use CT scan imaging to identify which smokers will develop COPD. To identify biomarkers predictive of smokers that will develop COPD. To determine if sputum (phlegm) can be analyzed to predict which smokers will develop COPD. Procedures (methods): All participants will undergo study related qu... Read More
Gender:
All
Ages:
Between 30 years and 55 years
Trial Updated:
03/25/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: COPD, Early-Onset
Register for Updates
LINK-HF2 - Remote Monitoring Analytics in Heart Failure
NCT04502563
Recruiting
Heart failure (HF) is a type of heart disease that leads to need of admissions to the hospital during worsening of symptoms. These admissions are expensive and very inconvenient for patients. The investigators have previously shown that monitoring of patients with a using a small wearable sensor combined with a mathematical model can detect worsening of HF before the patient needs medical care. In this study the investigators will test whether the remote monitoring and prediction of HF worsenin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah
Conditions: Heart Failure
Register for Updates
Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
NCT06329414
Recruiting
The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS. Participants will receive outpatient TMS treatment over the course of 5-6 weeks. Participants will complete validated questionnaires and exams before, during, and after treatment.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/22/2024
Locations: University of Utah Health, Salt Lake City, Utah
Conditions: Multiple Sclerosis, Major Depressive Disorder, Treatment Resistant Depression
Register for Updates
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349
Recruiting
The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult participants with primary ITP.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: Community Cancer Trials of Utah, Ogden, Utah
Conditions: Primary Immune Thrombocytopenia (ITP)
Register for Updates
M6®-C Artificial Cervical Disc Two-Level IDE Pivotal Study
NCT04982835
Recruiting
Prospective, concurrently controlled, multi-center study to evaluate the safety and effectiveness of the Spinal Kinetics M6-C™ artificial cervical disc compared to anterior cervical discectomy and fusion (ACDF) for the treatment of contiguous two-level symptomatic cervical radiculopathy at vertebral levels from C3 to C7 with or without spinal cord compression.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/22/2024
Locations: University of Utah Medical Center, Salt Lake City, Utah
Conditions: Cervical Disc Degenerative Disorder
Register for Updates
Intermountain Inpatient Bilirubin Decision Accuracy Study Using Smartphone-based Measurements by Picterus Jaundice Pro
NCT06329843
Recruiting
The goal of this project is to evaluate the performance of Picterus Jaundice Pro in an American population, including preterm and term newborns and pre- and post- phototherapy.
Gender:
All
Ages:
Between 12 hours and 192 hours
Trial Updated:
03/21/2024
Locations: Intermountain Health, Salt Lake City, Utah
Conditions: Neonatal Jaundice
Register for Updates
Real World Registry for Use of the Ion Endoluminal System
NCT06004440
Recruiting
The primary objective of this study is to evaluate the performance of the Ion Endoluminal System with real-world use for pulmonary lesion localization or biopsy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Intermountain Medical Center, Murray, Utah
Conditions: Lung Cancer, Multiple Pulmonary Nodules, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases
Register for Updates
Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)
NCT05631223
Recruiting
This will be a single-arm interventional study to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and disease activity in patients with psoriatic arthritis (PsA).
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
03/21/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Psoriatic Arthritis
Register for Updates
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
NCT05420636
Recruiting
This is a non-randomized single-arm, two cohorts, phase II study of iadademstat in combination with weekly paclitaxel in patients with relapse/refractory SCLC or extrapulmonary G3 Neuroendocrine Carcinomas. A total of 42 patients with SCLC (21 patients) and G3 NEC (21 patients) will be enrolled (including those enrolled in the safety lead-in portion).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Small-cell Lung Cancer, Neuroendocrine Carcinoma
Register for Updates